![Oligonucleotide Therapeutics Society](/img/default-banner.jpg)
- 143
- 204 952
Oligonucleotide Therapeutics Society
United States
Приєднався 8 гру 2015
The Oligonucleotide Therapeutics Society (OTS) is an open, nonprofit forum to foster research and development of oligonucleotide therapeutics.
The Founders’ vision was to bring together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential. A new era of oligonucleotide drugs was envisioned that would change the landscape of therapeutic modalities.
Oligonucleotide therapeutics are now being used to successfully treat diseases and have the potential for widespread application. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. Incredibly, oligonucleotide therapeutics have also been used to create an individualized treatment for one single person with a rare, fatal disease.
The Founders’ vision was to bring together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential. A new era of oligonucleotide drugs was envisioned that would change the landscape of therapeutic modalities.
Oligonucleotide therapeutics are now being used to successfully treat diseases and have the potential for widespread application. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. Incredibly, oligonucleotide therapeutics have also been used to create an individualized treatment for one single person with a rare, fatal disease.
Annual Meeting Poster Awardee Spotlight Webinar
OTS 2023 poster winners are presenting their research at the OTS webinar series.
Talk #1
Topic: Functional Aptamer Selection for the Low-Complexity Domain of TDP-43 as a Potential Treatment Avenue for ALS
Speaker: Daniel Knight, Carleton University
Talk #2
Topic: Characterization of Acute Myeloid Leukemia specific -DNA aptamers
Speaker: Bahareh Hosseinpour, Carleton University
Talk #1
Topic: Functional Aptamer Selection for the Low-Complexity Domain of TDP-43 as a Potential Treatment Avenue for ALS
Speaker: Daniel Knight, Carleton University
Talk #2
Topic: Characterization of Acute Myeloid Leukemia specific -DNA aptamers
Speaker: Bahareh Hosseinpour, Carleton University
Переглядів: 84
Відео
David Sabatino | Branching into RNAi
Переглядів 20514 днів тому
Title: Branching into RNAi Speaker: David Sabatino Associate Professor Carleton University Description: Our research focuses on the synthetic short-interfering RNAs (siRNAs) that silences the oncogenic mRNA expression of the Glucose Regulated Proteins (GRPs) leading to cancer cell death via the RNA interference (RNAi) pathway. To potentiate siRNA activity, we have developed the branch and hyper...
Antisense approaches for the treatment of Duchenne muscular dystrophy | Aurélie Goyenvalle
Переглядів 317Місяць тому
Antisense approaches for the treatment of Duchenne muscular dystrophy and recent advances to address DMD brain comorbidities This presentation will cover the development of ASO-based approaches for the treatment of Duchenne muscular dystrophy (DMD) and the recent possibilities to address DMD brain comorbidities. In addition to the progressive muscle weakness and degeneration which are character...
2023 Annual Meeting Poster Awardee Spotlight | Stan and Moravčík
Переглядів 100Місяць тому
2023 Annual Meeting Poster Awardee Spotlight | Stan and Moravčík Title: Validation lab: allowing standardized in vitro and in vivo experiments for candidate treatments for Duchenne muscular dystrophy Description: The Validation Lab was established in 2015 with support from the Duchenne Parent Project Netherlands to fill the need for an experienced and independent laboratory in DMD field. It u...
Eliot Morrison | In silico siRNA Off Target Predictions: What Should We Be Looking For?
Переглядів 3262 місяці тому
Assessing sequence-dependent off-target risks is a critical step during siRNA development to ensure the safety and specificity of therapeutic candidate molecules. This process starts during in-silico siRNA design, where potential RNAi-mediated off-targets are first predicted. This webinar provides an overview of how this has traditionally been approached and explores potential blind spots of su...
Jean Paul Desaulniers | In vivo Optical Control of Gene Silencing in Japanese Medaka Fish Embryos
Переглядів 2702 місяці тому
The siRNA oligonucleotide duplex inherent to biology, functions by binding and cleaving mRNA, a process known as the RNA interference (RNAi) pathway. Our lab has taken an interest in designing tetrafluorinated azobenzene, which has the unique ability to switch conformation from a trans to cis state when exposed to light. The ortho-functionalized, tetrafluorinated azobenzene was integrated into ...
RNA Targeting Technology - Chemistry and Delivery | Richard Geary
Переглядів 9413 місяці тому
OTS Webinar by OTS president Richard Geary www.oligotherapeutics.org/
2023 Annual Meeting Poster Awardee Spotlight Webinar
Переглядів 2024 місяці тому
2023 Annual Meeting Poster Awardee Spotlight Webinar www.oligotherapeutics.org/
OTS 2024 OTS Trainee Reps Introduction Webinar
Переглядів 2354 місяці тому
The OTS is happy to introduce our new trainee reps: Eva Maria Manz: Advancing Therapeutic Approaches for Erythropoietic Protoporphyria Jathavan Asohan: Self Assembled Nanoparticles For Delivering Functional Nucleic Acids
Anastasia Kremer & Linda Popella: 2023 Annual Meeting Poster Awardee Spotlight
Переглядів 1385 місяців тому
siRNA therapy for ex vivo treatment of stem cell grafts and/or donor lymphocytes Anastasia Kremer Allogeneic T cells represent the most potent treatment for hematopoietic malignancies such es leukemia. However, after interaction with host antigen-presenting cells, T cells can lead to the unwanted Graft-versus-Host Disease (GvHD) or the desired Graft-versus-Leukemia (GvL) effect. In contrast to ...
Preconference Session: Next-Gen Early Career Scientist Session
Переглядів 2105 місяців тому
This session provides a unique platform for student voices to be heard, and we have a great set of talks for you all to enjoy from students from all over the world. oligotherapeutics.org
Sudhir Agrawal, MSc, Phil | 2022 Award Recipient
Переглядів 8487 місяців тому
Evolution of Chemistry in the Development of RNA Therapeutics: Three decades later Sudhir Agrawal, MSc, Phil, UMASS Chan Medical School oligotherapeutics.org
Cy Stein, MD, PhD | 2023 Award Recipient
Переглядів 937 місяців тому
Phosphorothioates and me: Reflections on a life time of experimentation Cy Stein, MD, PhD, Author, Professor of Medicine oligotherapeutics.org
David Liu: Base Editing and Prime Editing (Correcting Mutations that Cause Genetic Disease)
Переглядів 4 тис.7 місяців тому
Base Editing and Prime Editing: Correcting Mutations that Cause Genetic Disease in Cells, Animals, and Patients Keynote Presentation by David Liu, PhD, The Broad Institute, Harvard University
Innovating and Commercializing the Next Generation of Oligonucleotide Therapeutics
Переглядів 6977 місяців тому
Pre Conference Educational Workshop on Innovating and Commercializing the Next Generation of Oligonucleotide Therapeutics from the Oligomeeting 2023.
Matthew Stanton: Non-viral DNA delivery: Opportunities and challenges
Переглядів 8458 місяців тому
Matthew Stanton: Non-viral DNA delivery: Opportunities and challenges
Amy Byrnes: ASO activity and distribution after LNP delivery
Переглядів 4829 місяців тому
Amy Byrnes: ASO activity and distribution after LNP delivery
Karyn O’Neil: Muscle targeted siRNA Conjugates for Pompe Disease
Переглядів 1 тис.10 місяців тому
Karyn O’Neil: Muscle targeted siRNA Conjugates for Pompe Disease
Shalini Andersson: Developing Oligonucleotides Into Therapies
Переглядів 2,1 тис.11 місяців тому
Shalini Andersson: Developing Oligonucleotides Into Therapies
Tim Yu: OTS Pathways for Patient Centered Interventional Genomic Medicine
Переглядів 338Рік тому
Tim Yu: OTS Pathways for Patient Centered Interventional Genomic Medicine
Art Krieg: Introduction to Nucleic Acid Immunity & Implications for Optimizing Cancer Immunotherapy
Переглядів 576Рік тому
Art Krieg: Introduction to Nucleic Acid Immunity & Implications for Optimizing Cancer Immunotherapy
OTS Trainee Spotlight Series: Remko Goossens & Priyanka Shukla
Переглядів 138Рік тому
OTS Trainee Spotlight Series: Remko Goossens & Priyanka Shukla
Laura Sepp Lorenzino: The Promise of CRISPR Therapeutics In Vivo and Cell Therapy Applications
Переглядів 400Рік тому
Laura Sepp Lorenzino: The Promise of CRISPR Therapeutics In Vivo and Cell Therapy Applications
Mano Manoharan: The World of GalNAc Conjugates in Nucleic Acid Therapeutics
Переглядів 1,6 тис.Рік тому
Mano Manoharan: The World of GalNAc Conjugates in Nucleic Acid Therapeutics
Trainee Spotlight Series: Tracy L Mallette & Jeremy Hall
Переглядів 118Рік тому
Trainee Spotlight Series: Tracy L Mallette & Jeremy Hall
Trainee Spotlight Series: OTS 2022 poster winners 2
Переглядів 226Рік тому
Trainee Spotlight Series: OTS 2022 poster winners 2
Prof. Jon Watts - Spotting Stubborn Indirect Effects in Oligonucleotide Therapeutics
Переглядів 557Рік тому
Prof. Jon Watts - Spotting Stubborn Indirect Effects in Oligonucleotide Therapeutics
Towards Developing Greener Methods for Oligonucleotide Synthesis
Переглядів 3,2 тис.Рік тому
Towards Developing Greener Methods for Oligonucleotide Synthesis
Trainee Spotlight Series: OTS 2023 Junior Board Members
Переглядів 179Рік тому
Trainee Spotlight Series: OTS 2023 Junior Board Members
Amazing informative video, I liked it a lot! And props to the speaker, she's really clear and experienced while delivering difficult points throughout the video.
Based on this video, we're now in the prime time for gene editing.
any inroads into MPN blood disorders?
Very informative and in-depth lecture on oligonucleotides
so what recourse is there for those of us who have Myeloproliferative neoplasms, like Polycythemia Vera?
Thank you.
Congratulations to Dr. Sudhir Agarwal, a giant in the field!
🤣 P r o m o S M
Yet again, the next white overly praised guy. What a surprise.😮😮😮
Sweet universe of nonsense!! How is it possible uni professors are REQUIRED to actually speak the language in which they deliver a conference!?? For crying out loud, the French are truly the worst! And I am bilingual myself!!!
thanks
5:29
17:00
really nice work!
Amazing work...
Great Talk, and great job. Dr. Lee.
A beautiful lecture with the benefit of hindsight.
The absolute GOAT
Incredible speaker with a very comprehensive presentation, thank you for this!
Thank you so much very helpful. May I ask about some of the design tools or software for miRNA/ anti-miRNA that I can use, please? I am a beginner in this field. Thank you so much.
It’s quite obvious that science is just beginning to understand the function of RNA and DNA for that matter. So maybe someone can explain to me, why the world would be receiving An mRNA vaccine that has no long term testing. That has skipped animal trials. Unless your objective is genocide, why in the world would this be released onto the public
what type of software do you recommend while working with aptamers
Thank you for making this available to the public.
The same way you synthesize or use gain of function on new virus species. I mean, the coronavirus shares a part of the same sequence as Moderna mRNA vaccine. Gotta love this plandemic.
Always look forward to these vids!
18:15 So that's why Moderna used a "platform approach" to assume tox and biodistribution data of similar LNPs while stating the payload inside is irrelevant? [Source] Joseph Senn Labroots Webinar _(had to screencap bc they deleted off YT)_
Figured my comment would be deleted for putting the **title,** bc YT loves censorship: _Evolution of a Platform Based Non-Clinical Assessment Approach for Vaccines_
Chemist, back to the bench!
Wow. amazing speaker. Great talk!
The MBBS (Bachelor of Medicine and Bachelor of Surgery) is a course that involves 4 years of study
Need hemophilia A, cure hurry up
to much "uuhmmm"
I don't trust anyone who uses uh uh uh in every sentence. If it were a drinking game you would die.
Kinda like how fast they built the bomb.
Hemophilia A hurry up
Great talk. Thanks for this presentation!
Hello mam
hemophilia A
hemophilia A cure need hurry
we need more data 🤓
I am super excited that Dr Madida 's herbal medicine that my boyfriend found on UA-cam was able to cure us of our herpes virus.
It was a great talk.Thanks
Hepatitis B can be treated reach out to Dr.Ayomede on his UA-cam channel for permanent cure
Thanks for sharing! In my opinion, it is ASO's that will fix diseases like ALS, MS, etc. It seems promising in treating SMA.
Can we get the slides?
Great presentation :-) Thanks.
Glad you liked it!
Thank you, it's so clear
Hi, can Ataxia Telangiectasia be treated with antisense oligonucleotide gene therapy ?
Yes, ASO therapies are in development. To my knowledge there is an n=1 trial ongoing see www.atcp.org/a-t-aso-gene-therapy-trial-continues/
It seems that MiRNA therapy has a bright future. When can we get an actual cancer medicine ?
After 4 yrs, how many CMOs have the ability to produce nucleotides in a large enough amount?
48:15 That one figure predicts the death of all standard AAV gene therapy companies. Nice work there!